150 results
Page of 13
  • ARRAY 797-301

    A phase 3, multinational, randomized, placebo-controlled study of ARRY-371797 in patients with symptomatic dilated cardiomyopathy due to a lamin A/C gene mutation.

    Type: Drug trial

    Principal Investigator: Saurabh Kapoor, MD

    Trial is not open for enrollment

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • HeartMate 3/ MOMENTUM 3

    A multicenter study of MagLev technology in patients undergoing MCS therapy with HeartMate 3.

    Type: Device trial

    Principal Investigator: Mark J. Zucker, MD, JD

    Trial is open for enrollment

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • PARTNER 3

    A multicenter, prospective, randomized, controlled study to establish the safety and effectiveness of the SAPIEN 3 transcatheter heart valve (THV) in low-risk patients requiring aortic valve replacement who have severe, calcific, symptomatic aortic stenosis.

    Type: Device trial

    Principal Investigator: Mark Russo, MD

    Trial is open for enrollment

    For inquiries, call (973) 926-6938
    • Newark Beth Israel Medical Center
    • Heart and Vascular Care
  • A011104 / 6694

    Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer. The J. Phillip Citta Cancer Center provides patients access to national and regional clinical research studies. The availability of these studies in the treatment of cancer, chemoprevention, and supportive care allow patients the option to participate in the latest treatment options including investigational drugs.

    For more information, please call Lennette Gonzales, RN, MSHS, OCN, CCRP, Oncology Research Registered Nurse as the J. Phillip Citta Regional Cancer Center

    For inquiries, call (732) 557-8294
    • Community Medical Center
    • Breast Care
    • Cancer
  • CK-SAPBI

    A Multi-Institutional Registry for CyberKnife Stereotactic Accelerated Partial Breast Irradiation. The J. Phillip Citta Cancer Center provides patients access to national and regional clinical research studies. The availability of these studies in the treatment of cancer, chemoprevention, and supportive care allow patients the option to participate in the latest treatment options including investigational drugs.

    For more information, please call Lennette Gonzales, RN, MSHS, OCN, CCRP, Oncology Research Registered Nurse as the J. Phillip Citta Regional Cancer Center

    For inquiries, call (732) 557-8294
    • Community Medical Center
    • Breast Care
    • Cancer
  • NRG-BR003

    A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

    For more information, please call Lennette Gonzales, RN, MSHS, OCN, CCRP, Oncology Research Registered Nurse as the J. Phillip Citta Regional Cancer Center

    For inquiries, call (732) 557-8294
    • Community Medical Center
    • Breast Care
    • Cancer
  • Lung Cancer Screening Registry

    The ACR Lung Screening Registry (LCSR) is designed to systematically audit the quality of interpretation of screening lung CT exams. The J. Phillip Citta Cancer Center provides patients access to national and regional clinical research studies. The availability of these studies in the treatment of cancer, chemoprevention, and supportive care allow patients the option to participate in the latest treatment options including investigational drugs.

    For more information, please call Lennette Gonzales, RN, MSHS, OCN, CCRP, Oncology Research Registered Nurse as the J. Phillip Citta Regional Cancer Center

    For inquiries, call (732) 557-8294
    • Community Medical Center
    • Lung
    • Cancer
  • RTOG 1306

    A Randomized Phase II study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC). The J. Phillip Citta Cancer Center provides patients access to national and regional clinical research studies. The availability of these studies in the treatment of cancer, chemoprevention, and supportive care allow patients the option to participate in the latest treatment options including investigational drugs.

    For more information, please call Lennette Gonzales, RN, MSHS, OCN, CCRP, Oncology Research Registered Nurse as the J. Phillip Citta Regional Cancer Center

    For inquiries, call (732) 557-8294
    • Community Medical Center
    • Lung
    • Cancer
  • A151216

    Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). The J. Phillip Citta Cancer Center provides patients access to national and regional clinical research studies. The availability of these studies in the treatment of cancer, chemoprevention, and supportive care allow patients the option to participate in the latest treatment options including investigational drugs.

    For more information, please call Lennette Gonzales, RN, MSHS, OCN, CCRP, Oncology Research Registered Nurse as the J. Phillip Citta Regional Cancer Center

    For inquiries, call (732) 557-8294
    • Community Medical Center
    • Lung
    • Cancer
  • A081105

    A Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC). The J. Phillip Citta Cancer Center provides patients access to national and regional clinical research studies. The availability of these studies in the treatment of cancer, chemoprevention, and supportive care allow patients the option to participate in the latest treatment options including investigational drugs.

    For more information, please call Lennette Gonzales, RN, MSHS, OCN, CCRP, Oncology Research Registered Nurse as the J. Phillip Citta Regional Cancer Center

    For inquiries, call (732) 557-8294
    • Community Medical Center
    • Lung
    • Cancer
  • E4512

    A Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for patients with tumors harboring the ALK fusion protein. The J. Phillip Citta Cancer Center provides patients access to national and regional clinical research studies. The availability of these studies in the treatment of cancer, chemoprevention, and supportive care allow patients the option to participate in the latest treatment options including investigational drugs.

    For more information, please call Lennette Gonzales, RN, MSHS, OCN, CCRP, Oncology Research Registered Nurse as the J. Phillip Citta Regional Cancer Center

    For inquiries, call (732) 557-8294
    • Community Medical Center
    • Lung
    • Cancer
  • EA5142

    Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab after Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers. The J. Phillip Citta Cancer Center provides patients access to national and regional clinical research studies. The availability of these studies in the treatment of cancer, chemoprevention, and supportive care allow patients the option to participate in the latest treatment options including investigational drugs.

    For more information, please call Lennette Gonzales, RN, MSHS, OCN, CCRP, Oncology Research Registered Nurse as the J. Phillip Citta Regional Cancer Center

    For inquiries, call (732) 557-8294
    • Community Medical Center
    • Lung
    • Cancer
Page of 13